Category: Company Updates

This category can only be viewed by members. To view this category, sign up by purchasing One Year Individual Subscription, One Year Individual Subscription (Digital), Two Year Individual Subscription, Two Year Individual Subscription (Digital), Three Year Individual Subscription, Three Year Individual Subscription (Digital), One Year Group Subscription, One Year Group Subscription (Digital), Two Year Group Subscription, Two Year Group Subscription (Digital), Three Year Group Subscription or Three Year Group Subscription (Digital).

Pharmacyclics Update (2-21-13)

Abbott To Develop Diagnostic for p17 del Gene in High-Risk CLL for PCYC/JNJ – Abbott Labs announced that it would collaborate with PCYC and JNJ to develop a companion diagnostic test using their FISH technology to identify patients with high-risk CLL patients that present with a deletion of the p17 chromosome. As a reminder, ibrutinib[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Pharmacyclics Update (2-15-13)

PCYC held its quarterly call this week, two days after announcing the receipt of a “Breakthrough Therapy Designation” from the FDA for ibrutinib in refractory MCL/WM. The plethora of positive data continues to build for ibrutinib, and management confirmed the NDA filing for relapsed/refractory MCL by year-end. No one knows exactly what the new designation[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Sangamo Update (2-13-13)

QUARTERLY UPDATE – stock has been volatile since the release of their financials last week (2/7). However, given that the stock has had an incredible start to 2013 (still up >50% YTD), a pullback was not unexpected, and the shares have since made an impressive recovery.  Pullbacks after very strong moves that back and fill[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Celgene Update (2-09-13)

Pomalyst (“Pom”) was approved by the FDA for the treatment of multiple myeloma (MM) patients who have failed two prior therapies, providing the beginning of another growth driver for CELG. The Fast Track approval was based on response rates. Despite being the third “imid,” Pom’s label has a black box warning (just like Revlimid &[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Celgene Update (2-21-13)

“Celgene Announces Accelerated $600 Million Share Repurchase Program” In a clear sign of optimism about its corporate outlook, CELG today announced it would accelerated share repurchases of $600 million of the company’s common stock, representing approximately 1.4% of shares outstanding. The long-awaited PFS data for the Revlimid MM-020 trial is due end-Q2/early Q3. With renewed growth[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Incyte Update (2-15-13)

Incyte’s Q4:12 results exceeded Wall Street’s expectations, driving the stock up 10%.  Sales of Jakafi were strong, but more importantly, the Company’s guidance for 2013 was impressive and could prove conservative. It appears new COO Jim Daly, who joined INCY in October from Amgen, is having a very positive impact, effectively educating physicians of the[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

OncoGenex Update (2-13-13)

OGXI has started their fourth Phase II trial testing OGX-427 in cancer patients.  Borealis-2 is being initiated as an investigator-sponsored, randomized, controlled Phase II trial of 427 in patients with advanced or metastatic bladder cancer (http://clinicaltrials.gov/ct2/show/NCT01454089?term=Oncogenex&rank=1). This trial will evaluate the potential of ‘427 to work synergistically with second- or third-line chemotherapy to overcome treatment[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Pharmacyclics Update (1-31-13)

PCYC = Janssen (JNJ) To Begin Front-Line Phase III Mantle Cell Lymphoma and Phase II Refractory Follicular Lymphoma Studies. We have discovered that www.clinicaltrials.gov recently (1/29) posted two new ibrutinib studies. First, and most important in our view, is the Phase III trial of ibrutinib in front-line mantle cell lymphoma (MCL) in combination with bendamustine[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (2-19-13)

GSK Begins Pivotal Trial For ISIS-TTR.  The company earned a $7.5 million milestone payment from their partner, GlaxoSmithKline (GSK), on the initiation of a Phase II/III trial for ISIS-TTR.  ISIS-TTR is an antisense drug development candidate for the treatment of transthyretin (TTR) amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

[*Breaking News*] Pharmacyclics Update (3-6-13)

Janssen (JNJ) Begins Ibrutinib Long-Term Extension Study. Pharmacyclics’ partner Janssen has filed to begin a Phase 3b study, enrolling 200 patients who have participated in ibrutinib studies. This is a long-term follow-up study to give patients ibrutinib for up to 3 years, a logical trial to continue to monitor the long-term safety and efficacy of[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

[*Breaking News*] Pharmacyclics Update (2-12-13)

FDA Grants Ibrutinib Breakthrough Therapy Designation – Could Be On The Market in Q1:14 – Raising BUY LIMIT and TARGET PRICE. The FDA has granted PCYC’s ibrutinib Breakthrough Therapy Designation for the treatment of relapsed/refractory mantle cell lymphoma (MCL) and Waldenstrom’s macroglubinemia (WM). This is a major positive for Pharmacyclics that could conceivably lead to[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

[*Breaking News*] Isis Update (1-31-13)

Isis’ Kynamro was approved by the FDA for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). The approval is the first for a systemic antisense drug (Vitravene for CMV of the eye was approved in 1998), and represents a major milestone for the Company’s antisense technology. The FDA approval triggers a $25 million milestone payment[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by